Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.

about

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.

P2860

Q47661608-B8D8E5E8-700D-416A-96C8-700F73E0A599

P2860

Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.

Item

http://www.wikidata.org/entity/Q39457284

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical outcomes in patients ...... Sydney Local Health District.

@en

Clinical outcomes in patients ...... Sydney Local Health District.

@nl

type

Item

label

Clinical outcomes in patients ...... Sydney Local Health District.

@en

Clinical outcomes in patients ...... Sydney Local Health District.

@nl

prefLabel

Clinical outcomes in patients ...... Sydney Local Health District.

@en

Clinical outcomes in patients ...... Sydney Local Health District.

@nl

P1476

Clinical outcomes in patients ...... n Sydney Local Health District

@en

P2093

Joseph Descallar

http://www.w3.org/2001/XMLSchema#string

Po Y Yip

http://www.w3.org/2001/XMLSchema#string

Wei Chua

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

Inflammation and cancer

Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Inflammation and cancer: back to Virchow?

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

1405-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.13555

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28742280

http://www.w3.org/2001/XMLSchema#string

Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.

about

P2860

P2860

Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698